---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Care management intervention strategies"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Care management intervention strategies. Topics: Treat-to-target strategy: National Psoriasis Foundation Delphi consensus on instrument and evaluation timing, Treatment goal monitoring and therapy modification: guideline, Tuberculosis screening before and during biologic or deucravacitinib therapy: guideline, Latent tuberculosis testing for IL-17 and IL-23 inhibitors: NPF and IPC joint position, and 15 further topics. 19 evidence topics quoted from 19 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/care-management-intervention-strategies"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Care management intervention strategies

<a id="heading-2.2.2.4"></a>

## 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

### Treat-to-target strategy: National Psoriasis Foundation Delphi consensus on instrument and evaluation timing

> “The National Psoriasis Foundation conducted a consensus-building study among psoriasis experts using the Delphi method.”
> “A total of 25 psoriasis experts participated in the Delphi process.”
> “The most preferred instrument was body surface area (BSA).”
> “The most preferred time for evaluating patient response after starting new therapies was at 3 months.”
> “During the maintenance period, evaluation every 6 months was most preferred.”
> “With defined treatment targets, clinicians and patients can regularly evaluate treatment responses and perform benefit-risk assessments of therapeutic options individualized to the patient.”

Source: [Armstrong et al. (2017a)](https://pubmed.ncbi.nlm.nih.gov/27908543/)

<a id="topic-2.2.2.4-2"></a>

### Treatment goal monitoring and therapy modification: guideline

> “Various forms of adjustment include increasing the dosage, initiation of combination therapy, or transitioning to another drug or procedure.”
> “Treatment goals must be determined individually with the patients in a joint decision‐making process.”
> “During maintenance therapy, control of treatment goals should be done at the same intervals as the general monitoring, usually every 8 to 12 weeks.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.2.4-3"></a>

### Tuberculosis screening before and during biologic or deucravacitinib therapy: guideline

> “A major focus of this update is the chapter on screening for tuberculosis as well as therapy selection and management in latent tuberculosis.”
> “We recommend excluding latent TB infection using interferon‐gamma release assay (IGRA) before initiating treatment with a biologic agent or deucravacitinib”
> “Deucravacitinib: due to lack of data concerning the reactivation risk”
> “We recommend against repeating IGRA just based on fixed time intervals or due to switching from one drug to another without relevant risk of exposure.”
> “We recommend repeating IGRA during treatment if there is an increased risk of TB exposure (see background text: Indications for an increased probability of an exposure risk).”

Source: [Nast et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12875186/)

<a id="topic-2.2.2.4-4"></a>

### Latent tuberculosis testing for IL-17 and IL-23 inhibitors: NPF and IPC joint position

> “Although testing for latent tuberculosis (TB) infection has been standard practice for psoriasis patients being treated with interleukin (IL) 17 or IL-23 inhibitors, evidence for this practice is weak.”
> “87.5% of the members from the National Psoriasis Foundation Medical Board and International Psoriasis Council approved a new Joint Position Statement regarding psoriasis patients being treated with IL-17 or IL-23 inhibitors, stating that testing for latent TB infection is not required.”
> “Psoriasis experts reached consensus that routine testing for latent TB infection is not required in psoriasis patients being treated with IL-17 or IL-23 inhibitors.”

Source: [Blauvelt et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/41260526/)

<a id="topic-2.2.2.4-5"></a>

### Tuberculosis testing requirement removed for risankizumab and absent for icotrokinra

> “Last week, the U.S. Food and Drug Administration (FDA) removed the tuberculosis (TB) testing requirement for the widely used drug risankizumab (Skyrizi), which is indicated for the treatment of psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.”
> “Following that published expert guidance, the FDA did not require TB testing for Johnson & Johnson’s new oral treatment icotrokinra (Icotyde).”

Source: [National Psoriasis Foundation, FDA drops TB testing for Skyrizi (2026)](https://www.psoriasis.org/us-fda-drops-tb-testing-requirement/)

> “Following review, the FDA determined that patients prescribed the therapy would not be required to undergo TB testing.”
> “TB testing has been a barrier for both patients and providers in the management of psoriatic disease, leading to anxiety, unnecessary treatment of TB due to false positive tests, unnecessary increases in medical costs, and delays in treatment of psoriasis”

Source: [National Psoriasis Foundation, TB testing for new oral treatment (2026)](https://www.psoriasis.org/tb-testing-new-oral-treatment/)

<a id="topic-2.2.2.4-6"></a>

### Hepatitis B and hepatitis C screening before systemic therapy: guideline

> “We recommend screening patients for hepatitis B (HBsAg, anti‐HBs, anti‐HBc) as a routine measure before starting a treatment with ciclosporin, deucravacitinib, methotrexate, or biologics.”
> “We suggest screening patients for hepatitis C as a routine measure before starting a treatment with deucravacitinib, methotrexate, or biologics.”
> “We recommend against screening for hepatitis A, D, or E as a routine measure before starting a systemic treatment.”
> “If viral hepatitis has been excluded once before initiating an immunosuppressive therapy and there is no history‐related/laboratory evidence of infection, re‐testing is not required when changing the therapy.”

Source: [Nast et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12875186/)

<a id="topic-2.2.2.4-7"></a>

### Pretreatment workup for deucravacitinib: guideline expert recommendations

> “Check need for vaccinations according to current vaccination recommendations including prophylactic vaccination against herpes zoster”
> “Inform patients to discontinue treatment and present for examination if they experience muscle weakness or pain, especially if these are accompanied by fatigue or fever.”
> “Not all tests may be required for all patients.”
> “The recommendations are based on expert opinions and take into account that the experience with the drug is still limited.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.2.4-8"></a>

### Vaccination timing and live vaccines during oral and biologic therapy

> “The optimal time for vaccinations is before starting a systemic immunosuppressive therapy.”
> “In general, inactivated vaccines can be used safely in patients receiving systemic immunosuppressive therapy.”

Source: [Nast et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12875186/)

> “Using a modified Delphi process, 22 consensus statements were developed by the National Psoriasis Foundation Medical Board and COVID-19 Task Force, and infectious disease experts.”
> “Key recommendations include continuing most oral and biologic therapies without modification for patients receiving nonlive vaccines; consider interruption of methotrexate for nonlive vaccines.”
> “For patients receiving live vaccines, discontinue most oral and biologic medications before and after administration of live vaccine.”

Source: [Chat et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38331098/)

<a id="topic-2.2.2.4-9"></a>

### Comorbidity screening: psoriatic arthritis at each visit and cardiovascular risk assessment

> “Screening patients with psoriasis for PsA is essential at each visit.”
> “CV risk assessment (screening for hypertension, diabetes, and hyperlipidemia) with national guidelines is recommended for all patients with psoriasis.”
> “Clinicians should consider early and more frequent screening for hypertension, diabetes, and hyperlipidemia in psoriasis patients who are candidates for systemic or phototherapy or who have psoriasis involving >10% of the BSA.”
> “Patients with moderate-to-severe psoriasis should have their obesity status determined annually.”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

> “We recommend working in collaboration with the treating gastroenterologists when prescribing a systemic therapy in psoriasis patients with concomitant chronic inflammatory bowel disease (IBD).”

Source: [Nast et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12875186/)

<a id="topic-2.2.2.4-10"></a>

### Telemedicine management of psoriasis

> “Telemedicine utilization among dermatologists increased from under 15% to >95% after the pandemic, reflecting its marked popularity among patients and uptake for physicians.”
> “As compared with in-person care, collaborative and efficient teledermatology models equivalently improve PASI scores, BSA, and dermatology life quality index.”
> “Teledermatology is a reasonable alternative for providing long-term management of patients with psoriasis.”
> “It is important to guarantee the accessibility of in-person care for patients with psoriasis and ensure that telemedicine does not supplant such availability.”
> “The PEST should be provided to patients every 6 months to screen for PsA to help mitigate the undertreatment and delay in the diagnosis of this common comorbidity in patients with psoriasis.”

Source: [Pelet Del Toro et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10238745/)

<a id="topic-2.2.2.4-11"></a>

### Online and in-person care: 12-month randomized equivalency trial in 296 adults

> “Overall, 296 adults with physician-diagnosed psoriasis from ambulatory clinics were randomly assigned to either online or in-person care; all were analyzed for outcomes.”
> “Across 12 months, for the online group, the mean ± standard deviation decline in Skindex-16 from baseline across follow-up visits was 9.02 ± 20.67 compared with 10.55 ± 23.50 for the in-person group.”
> “Over the 12-month study period, the in-person group had a total of 315 in-person visits; the online group had 161 online visits.”

Source: [Armstrong et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6599714/)

<a id="topic-2.2.2.4-12"></a>

### Shared decision-making aid for biologic choice: dosing interval by agent

> “This is a decision aid to help clinicians and patients decide their treatment choice and is not a comprehensive data source or replacement for the individual drug summary of product characteristics.”

Source: [Smith et al. (2024a)](https://academic.oup.com/bjd/article/190/2/270/7280929)

| Agent | How often do I need to inject the treatment? |
| --- | --- |
| Adalimumab | “Every other week” |
| Certolizumab pegol | “Every 2 weeks” |
| Etanercept | “Once or twice a week” |
| Infliximab | “Every 8 weeks” |
| Ustekinumab | “Every 12 weeks” |
| Bimekizumab | “Every 8 weeks” |
| Brodalumab | “Every 2 weeks” |
| Ixekizumab | “Every 4 weeks” |
| Secukinumab | “Every month” |
| Guselkumab | “Every 8 weeks” |
| Risankizumab | “Every 12 weeks” |
| Tildrakizumab | “Every 12 weeks” |

Source: [Smith et al. (2024a)](https://academic.oup.com/bjd/article/190/2/270/7280929)

<a id="topic-2.2.2.4-13"></a>

### Pharmacy-led prior authorization management in dermatology

> “Biologic agents (55.2%) and brand-name only medications (42.8%) required PA at higher rates.”
> “Pharmacy intervention resulted in shorter time to PA submission (4 days vs 1 day, P < .001) and decision (6 days vs 1 day, P < .001) and higher approval rates (63.9% vs 80.6%, P < .001) but did not decrease the total number of PAs.”
> “Patients with approved PAs had higher likelihood of disease improvement vs those with denied PAs (71.1% vs 58.0%, P = .013).”

Source: [Popatia et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31103568/)

<a id="topic-2.2.2.4-14"></a>

### Online prescription management and specialty pharmacy support: abandonment and time to first fill

> “HCPro patients had a lower abandonment rate (6.4% vs. 13.9%; P < 0.001) and reduced days to prescription fill (7.0 vs. 14.4; P < 0.001).”
> “After controlling for baseline characteristics, abandonment odds were 43% lower for patients using HCPro (odds ratio = 0.57; P = 0.004).”

Source: [Hawkes et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6822976/)

<a id="topic-2.2.2.4-15"></a>

### Adherence interventions including pharmacist-delivered models: systematic review of 26 studies

> “Twenty-six studies were included.”
> “Digital and technology‐supported interventions, including mobile applications, short message service reminders and electronic monitoring‐supported platforms were the most frequently evaluated and were generally associated with modest improvements in adherence when compared to usual care.”
> “Healthcare professional‐led interventions such as nurse and pharmacist delivered models demonstrated potential benefits in adherence.”
> “Across studies, improvements in adherence were more consistently observed than improvements in clinical severity and quality‐of‐life outcomes.”

Source: [Kumar et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13570483/)

<a id="topic-2.2.2.4-16"></a>

### Step therapy before specialty medication: time to second referral in psoriasis and atopic dermatitis

> “The included patients (N = 83) were predominantly White (75%) and female (61%) with a median age of 50 years (interquartile range [IQR] = 37-61 years).”
> “62 patients were required to use step therapy, and 21 were required to use a formulary alternative.”
> “Of the patients required to use step therapy, 37 (60%) had a second referral for a specialty medication because of failing step therapy requirements, with a median time to a second referral of 75 days (IQR = 27-135).”

Source: [Bowles et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11852794/)

> “One study analyzing 194 step therapy protocols for PsO found that none were consistent with current clinical treatment guidelines and that 99.4% were more stringent than current treatment guidelines”

Source: [Marquez-Grap et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12126447/)

<a id="topic-2.2.2.4-17"></a>

### Prior authorization burden, approval rates, and wait times for biologics

> “In September 2016, 626 PAs were generated from 9512 patient encounters.”
> “Biologic PAs cost a median of $15.80 each and took as long as 31 business days to complete.”
> “Approval rates were 99.6% for procedures, 78.9% for biologics, and 58.2% for other medications.”

Source: [Carlisle et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7450401/)

> “Records from the University of Miami Health System were reviewed, and 101 patients were included.”
> “Patients with Medicare had the shortest wait time with a mean of 7.3 days.”
> “Private insurance patients waited the longest, regardless of whether they had a PPO (37 days) or HMO (41.3 days).”

Source: [Vazquez et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36372843/)

<a id="topic-2.2.2.4-18"></a>

### German S3 guideline adapted from EuroGuiDerm, part 2: specific clinical and comorbid situations

> “S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – part 2: Specific clinical and comorbid situations”
> “The present Part 2 of the updated German S3 guideline on the treatment of psoriasis vulgaris provides recommendations for therapy selection in special clinical situations and in the presence of comorbidities.”

Source: [Nast et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12875186/)

<a id="topic-2.2.2.4-19"></a>

### British Association of Dermatologists guideline for biologic therapy: living guideline transition, decision aid update, and dosing question

> “The British Association of Dermatologists (BAD) published the fourth iteration of its clinical guideline for biologic therapy for people with moderate-to-severe psoriasis in 2020.”
> “In line with the BAD’s clinical guideline strategy, and in response to the rapidly changing developments in psoriasis therapeutics, the BAD guideline for biologics will be transitioning to a living guideline”
> “The GDG has also updated the decision aid.”
> “this is a research letter prepared for the Clinical Standards Unit of the British Association of Dermatologists (BAD), which includes the Therapy & Guidelines subcommittee.”
> “How often do I need to inject the treatment?”

Source: [Smith et al. (2024a)](https://academic.oup.com/bjd/article/190/2/270/7280929)

Additional sources: [Patel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41419127/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
